1. Home
  2. CRSP vs PCVX Comparison

CRSP vs PCVX Comparison

Compare CRSP & PCVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CRSP
  • PCVX
  • Stock Information
  • Founded
  • CRSP 2013
  • PCVX 2013
  • Country
  • CRSP Switzerland
  • PCVX United States
  • Employees
  • CRSP N/A
  • PCVX N/A
  • Industry
  • CRSP Biotechnology: Biological Products (No Diagnostic Substances)
  • PCVX Biotechnology: Pharmaceutical Preparations
  • Sector
  • CRSP Health Care
  • PCVX Health Care
  • Exchange
  • CRSP Nasdaq
  • PCVX Nasdaq
  • Market Cap
  • CRSP 4.9B
  • PCVX 4.4B
  • IPO Year
  • CRSP 2016
  • PCVX 2020
  • Fundamental
  • Price
  • CRSP $57.68
  • PCVX $34.82
  • Analyst Decision
  • CRSP Buy
  • PCVX Strong Buy
  • Analyst Count
  • CRSP 16
  • PCVX 10
  • Target Price
  • CRSP $70.73
  • PCVX $136.50
  • AVG Volume (30 Days)
  • CRSP 3.7M
  • PCVX 1.1M
  • Earning Date
  • CRSP 08-04-2025
  • PCVX 08-05-2025
  • Dividend Yield
  • CRSP N/A
  • PCVX N/A
  • EPS Growth
  • CRSP N/A
  • PCVX N/A
  • EPS
  • CRSP N/A
  • PCVX N/A
  • Revenue
  • CRSP $37,675,000.00
  • PCVX N/A
  • Revenue This Year
  • CRSP $28.31
  • PCVX N/A
  • Revenue Next Year
  • CRSP $268.05
  • PCVX N/A
  • P/E Ratio
  • CRSP N/A
  • PCVX N/A
  • Revenue Growth
  • CRSP N/A
  • PCVX N/A
  • 52 Week Low
  • CRSP $30.04
  • PCVX $27.66
  • 52 Week High
  • CRSP $71.13
  • PCVX $121.06
  • Technical
  • Relative Strength Index (RSI)
  • CRSP 52.32
  • PCVX 47.88
  • Support Level
  • CRSP $61.13
  • PCVX $35.46
  • Resistance Level
  • CRSP $69.58
  • PCVX $37.00
  • Average True Range (ATR)
  • CRSP 3.89
  • PCVX 1.43
  • MACD
  • CRSP -0.71
  • PCVX -0.14
  • Stochastic Oscillator
  • CRSP 28.46
  • PCVX 9.28

About CRSP CRISPR Therapeutics AG

Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.

About PCVX Vaxcyte Inc.

Vaxcyte Inc is a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its product comprises of Pneumococcal conjugate vaccine. The firm's product candidate consists of VAX-31, VAX-24, VAX-A1, VAX-PG, VAX-GI, and Others.

Share on Social Networks: